
JGB1741
CAS No. 1256375-38-8
JGB1741 ( ILS-JGB-1741 )
产品货号. M27505 CAS No. 1256375-38-8
JGB1741 是一种有效的选择性 SIRT1 抑制剂,IC50 为 15 μM。 JGB1741 调节 Bax/Bcl2 比率、细胞色素 c 释放和 PARP 裂解,并增加乙酰化 p53 水平,导致 p53 介导的细胞凋亡。 JGB1741可用于乳腺癌研究。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1442 | 有现货 |
![]() ![]() |
10MG | ¥2406 | 有现货 |
![]() ![]() |
25MG | ¥4236 | 有现货 |
![]() ![]() |
50MG | ¥6148 | 有现货 |
![]() ![]() |
100MG | ¥8586 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称JGB1741
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述JGB1741 是一种有效的选择性 SIRT1 抑制剂,IC50 为 15 μM。 JGB1741 调节 Bax/Bcl2 比率、细胞色素 c 释放和 PARP 裂解,并增加乙酰化 p53 水平,导致 p53 介导的细胞凋亡。 JGB1741可用于乳腺癌研究。
-
产品描述JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.(In Vitro):JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression.
-
体外实验JGB1741 (ILS-JGB-1741; 1-10000 nM; 24 h) inhibits MDA-MB 231 cell proliferation. JGB1741 (0.01-1 μM; 24 h) induces apoptosis of MDA-MB 231 cells. JGB1741 (0.01-1 μM; 24 h) shows a cell cycle arrest at G1 phase with more and more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM; 24 h) shows an increase in the global acetylation of H3K9, p53 expression and acetylated p53K382 levels. Cell Proliferation Assay Cell Line:K562, HepG2 and MDA-MB 231 cell lines Concentration:1, 10, 50, 100, 500, 1000, 10000 nM Incubation Time:24 hours Result:Inhibited MDA-MB 231 cell proliferation more potently with an IC50 of 0.5 μM than K562 and HepG2 cell proliferation (IC50>1 μM).Apoptosis Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Showed an increase in the percent apoptotic cells in a dose-dependent fashion with ~70% apoptosis at 1 μM concentration.Cell Cycle Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Showed a cell cycle arrest at G1 phase with more and more cells entering into sub G0/G1 phase, the apoptotic phase, in a dose-dependent fashion.Western Blot Analysis Cell Line:MDA-MB 231 cells Concentration:0.01, 0.1, 0.5, 1 μM Incubation Time:Result:Caused a dose-dependent increase in the global acetylation of H3K9. Showed an increase in both p53 expression and acetylated p53K382 levels.
-
体内实验——
-
同义词ILS-JGB-1741
-
通路Chromatin/Epigenetic
-
靶点Sirtuin
-
受体Aurora B
-
研究领域——
-
适应症——
化学信息
-
CAS Number1256375-38-8
-
分子量440.56
-
分子式C27H24N2O2S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 5 mg/mL (11.35 mM)
-
SMILESC(NCC1=CC=CC=C1)(=O)C=2C3=C(SC2/N=C/C=4C5=C(C=CC4O)C=CC=C5)CCCC3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.1. Naga Rajiv Lakkaniga,et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589.
产品手册




关联产品
-
Ophiopogonin D (b)
麦冬皂苷 D' 可以以剂量依赖性方式激活 SIRT1。 Ophiopogonin D' 还非竞争性抑制 UGT1A6 和 UGT1A10。
-
Nicotinamide ribosid...
烟酰胺核苷可增加 NAD[+] 水平并激活 SIRT1 和 SIRT3,最终增强氧化代谢并防止高脂肪饮食引起的代谢异常。
-
lithospermic acid B
Lithospermic Acid B 是一种从丹参提取物中提取的水溶性抗氧化剂。具有显着的抗氧化作用;抗血小板聚集、抗凝、抗血栓作用。